KO

KOREAN DRUG CO., LTD.

Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.

014570 | KO

Overview

Corporate Details

ISIN(s):
KR7014570006
LEI:
Country:
South Korea
Address:
경기도 이천시 신둔면 원적로 69-10, 이천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Korean Drug Co., Ltd. is an established pharmaceutical company with over 50 years of experience in developing, manufacturing, and marketing therapeutic drugs. The company's portfolio includes both prescription (ETC) medicines for various conditions and over-the-counter (OTC) products, such as its 'Geunalen' brand of painkillers. Leveraging state-of-the-art production facilities and proprietary technology, the company produces a range of finished pharmaceutical products, and its offerings may also extend to health supplements and medical supplies. The company is committed to developing high-quality medicines for public health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-13 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.2 KB
2025-08-11 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.5 KB
2025-07-02 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-06-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.6 KB
2025-06-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-06-02 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1019.2 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.7 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.6 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 18.4 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 444.5 KB
2025-03-06 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-03-04 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.5 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 102.6 KB

Automate Your Workflow. Get a real-time feed of all KOREAN DRUG CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOREAN DRUG CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOREAN DRUG CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.